Charles Schwab
DSGN icon

Charles Schwab’s Design Therapeutics DSGN Stock Holding History

Charles Schwab’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93M Buy
271,264
+29,779
+12% +$371K ﹤0.01% 2569
2026
Q1 		$2.57M Buy
241,485
+4,622
+2% +$46.8K ﹤0.01% 2643
2025
Q4 		$2.22M Sell
236,863
-11,071
-4% -$86.7K ﹤0.01% 2731
2025
Q3 		$1.87M Sell
247,934
-3,015
-1% -$15.1K ﹤0.01% 2765
2025
Q2 		$846K Sell
250,949
-7,426
-3% -$27.8K ﹤0.01% 2949
2025
Q1 		$997K Sell
258,375
-6,300
-2% -$30.1K ﹤0.01% 2844
2024
Q4 		$1.63M Buy
264,675
+7,243
+3% +$41.9K ﹤0.01% 2742
2024
Q3 		$1.38M Buy
257,432
+77,472
+43% +$364K ﹤0.01% 2810
2024
Q2 		$603K Buy
179,960
+790
+0.4% +$3.08K ﹤0.01% 3116
2024
Q1 		$722K Buy
179,170
+3,525
+2% +$9.41K ﹤0.01% 2895
2023
Q4 		$465K Buy
175,645
+2,100
+1% +$4.81K ﹤0.01% 3095
2023
Q3 		$410K Sell
173,545
-55,261
-24% -$258K ﹤0.01% 3116
2023
Q2 		$1.44M Sell
228,806
-1,541
-0.7% -$9.43K ﹤0.01% 2654
2023
Q1 		$1.33M Sell
230,347
-565
-0.2% -$4.23K ﹤0.01% 2637
2022
Q4 		$2.37M Buy
230,912
+6,352
+3% +$86.1K ﹤0.01% 2513
2022
Q3 		$3.75M Buy
224,560
+89,785
+67% +$1.79M ﹤0.01% 2371
2022
Q2 		$1.89M Buy
134,775
+12,407
+10% +$168K ﹤0.01% 2583
2022
Q1 		$1.98M Buy
122,368
+3,812
+3% +$58.4K ﹤0.01% 2651
2021
Q4 		$2.54M Buy
118,556
+28,035
+31% +$481K ﹤0.01% 2623
2021
Q3 		$1.33M Buy
90,521
+2,756
+3% +$45.8K ﹤0.01% 2786
2021
Q2 		$1.75M Buy
+87,765
New +$2.22M ﹤0.01% 2760

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's DSGN Position: Q2 2026 in Review

Charles Schwab increased its Design Therapeutics (DSGN) stake by 12% in Q2 2026, buying an estimated $371K and bringing the position to 271,264 shares worth $3.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2569.

Charles Schwab first reported a position in DSGN in Q2 2021 and has held it in 21 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Charles Schwab held 271,264 shares of Design Therapeutics worth $3.93M as of Q2 2026.
  • Charles Schwab bought 29,779 Design Therapeutics shares in Q2 2026, an estimated $371K.
  • Design Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2569 holding.
  • Charles Schwab first reported a position in Design Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.